Sheri Lydick

Ms. Lydick joins BioAtla with 20 years of leadership and commercialization experience in the biotechnology and pharmaceutical industry. In her most recent role at BMS, Ms. Lydick was responsible for building the sales and marketing teams and leading the commercial launch of Zeposia® across multiple therapeutic areas (multiple sclerosis and ulcerative colitis). In her twelve years (2007-2019) at Celgene her leadership role expanded from Director of Global Marketing for the Inflammation and Immunology (I&I) Franchise to Executive Director, US Rheumatology Lead, to Vice President, US Commercial Lead for Zeposia®. Mrs. Lydick was instrumental in building the I & I Franchise, including establishing priority diseases / markets of focus, defining global resource and capability requirements to support launches into competitive markets and leading the US launch of the blockbuster drug Otezla® in psoriatic arthritis. Prior to joining Celgene, Ms. Lydick held multiple worldwide marketing roles at ALTANA Pharma where she was responsible for developing the Global and US launch plans and ensuring worldwide launch preparedness for a first-in-class therapeutic in respiratory disease. Ms. Lydick received both her BSc degree in Zoology and Master of Science degree in Biochemistry and Molecular Biology from the University of Maine.